Medical College of Wisconsin
CTSIResearch InformaticsREDCap

Dermal elastolysis in the setting of combination immunotherapy. J Cutan Pathol 2019 Sep;46(9):684-687

Date

05/11/2019

Pubmed ID

31074019

DOI

10.1111/cup.13492

Scopus ID

2-s2.0-85067448497 (requires institutional sign-in at Scopus site)   7 Citations

Abstract

Multiple cutaneous side effects have been reported with the use of immunotherapies including programmed cell death protein 1 inhibitors. We report 2 patients who presented with papillary dermal elastolysis presenting as multiple, skin-colored, wrinkled papules and atrophic macules following an inflammatory eruption in the setting of combination chemotherapy with nivolumab and cabiralizumab. These two cases highlight a novel finding, elastolysis in the setting of chemotherapy with nivolumab and cabiralizumab.

Author List

Dickinson KE, Price L, Wanat KA, Swick BL

Author

Karolyn A. Wanat MD Chair, Professor in the Dermatology department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Antineoplastic Combined Chemotherapy Protocols
Bone Neoplasms
Dermis
Drug Eruptions
Female
Humans
Lung Neoplasms
Middle Aged
Neoplasm Metastasis
Osteosarcoma
Skin Pigmentation